{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Acetyl Hexapeptide-8",
    "short_name": "Argireline",
    "aliases": [
      "Argireline",
      "Acetyl hexapeptide-3"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Primarily used as a cosmetic ingredient. Not an FDA-approved therapeutic drug; typically regulated under cosmetics rather than prescription medications."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-17",
      "human_use_note": "Acetyl Hexapeptide-8 (Argireline) is widely used topically in cosmetic products for wrinkle/appearance claims. It is not an FDA-approved therapeutic drug, and product quality, concentration, and formulation vary by manufacturer."
    },
    "structure": {
      "sequence_oneletter": "",
      "amino_acid_seq": "",
      "molecular_formula": "",
      "molecular_weight": null,
      "structure_image_url": ""
    },
    "risk": {
      "current_score": 2,
      "severity": "mild",
      "likelihood": "unlikely",
      "evidence_grade": "human_interventional",
      "developmental_risk": false,
      "unknowns_penalty": true,
      "rationale": "Topical cosmetic use is generally associated with low systemic risk, and small human studies report few significant adverse events. However, evidence quality varies, formulation-dependent effectiveness is a major confounder, and long-term/high-exposure systemic safety is not well characterized."
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "moderate",
          "evidence_grade": "human_interventional",
          "text": "Acetyl Hexapeptide-8 (Argireline) is a synthetic cosmetic peptide commonly used topically in anti-aging skincare products. It is marketed for reducing the appearance of expression lines, with proposed effects related to neurotransmitter-mediated muscle contraction signaling in the skin.",
          "evidence_refs": ["E1", "E2"]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "topical",
          "unit": "formulation-dependent",
          "min": null,
          "max": null,
          "frequency": "varies",
          "duration": "varies",
          "population_group": "general",
          "notes": "Descriptive only. Cosmetic formulations vary widely by manufacturer; this entry does not provide usage instructions.",
          "evidence_refs": ["E1", "E2"]
        }
      ],
      "developmental_risk_block": [],
      "interaction_summary": []
    },
    "interactions": {
      "drug_classes": [],
      "supplement_classes": [],
      "peptides": []
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Investigating the effects of Argireline in a skin serum (clinical cosmetic study)",
        "source_type": "pmc",
        "source_id": "PMC10665711",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10665711/",
        "published_date": "2023-01-01",
        "evidence_grade": "human_interventional",
        "notes": "Small human study evaluating wrinkle score changes after several weeks of serum application; reports limited significant adverse events."
      },
      {
        "id": "E2",
        "title": "Acetyl Hexapeptide-8 in Cosmeceuticalsâ€”A Review of Skin Effects and Delivery Challenges",
        "source_type": "pubmed",
        "source_id": "40565185",
        "url": "https://pubmed.ncbi.nlm.nih.gov/40565185/",
        "published_date": "2025-01-01",
        "evidence_grade": "human_interventional",
        "notes": "Review summarizing preclinical/clinical evidence, formulation strategies, and uncertainties about penetration to targets."
      },
      {
        "id": "E3",
        "title": "Argireline in Treatment of Periorbital Wrinkles (ClinicalTrials.gov record)",
        "source_type": "clinicaltrials",
        "source_id": "NCT01381484",
        "url": "https://clinicaltrials.gov/study/NCT01381484",
        "published_date": "",
        "evidence_grade": "human_interventional",
        "notes": "Registry entry documenting a human study context for Argireline and periorbital wrinkles."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-17",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Acetyl Hexapeptide-8 (Argireline)",
        "detail": "Added cosmetic peptide entry with human study and review references; low-risk topical profile with uncertainty penalty due to formulation variability and limited long-term systemic characterization.",
        "evidence_refs": ["E1", "E2", "E3"]
      }
    ]
  }
}
